Complete Wegovy vs Mounjaro Dosage Switching Guide
Understanding Wegovy vs Mounjaro Dosage Differences for Switching
When comparing Wegovy vs Mounjaro dosage schedules, the fundamental difference lies in their escalation pathways and maintenance phases. Wegovy follows a structured 16-week dose escalation: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), then 2.4mg maintenance from week 17 onwards. This gradual increase supports gastrointestinal tolerability whilst building therapeutic efficacy.
Mounjaro (tirzepatide) employs a different approach, starting at 2.5mg and escalating by 2.5mg increments every 4 weeks, reaching maintenance doses of 5mg, 10mg, or 15mg depending on individual response and tolerability. The switching process between these medications requires careful consideration of equivalent dosing, with your prescriber determining the most appropriate transition schedule based on your current dose and treatment response.
Wegovy vs Mounjaro Dosage Cost Comparison and Savings
The financial advantage of switching becomes apparent when examining the Wegovy vs Mounjaro dosage pricing structure. Wegovy starter doses begin at £79.99 for 0.25mg, progressing to £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), and £209.99 for the 2.4mg maintenance dose. New customers apply code FIRST40 at checkout to reach these final prices, whilst returning customers use DOSE25.
Our Getting Started bundles provide additional value for dose escalation phases, with the Intro Duo (0.25mg & 0.5mg) at £169.99 and Progress Duo (0.5mg & 1mg) at £189.99. For patients requiring extended treatment at specific doses, our Consistency bundles offer 2-pen supplies: Consistency 1mg (×2) at £209.99 or Consistency 2.4mg maintenance (×2) at £419.99, ensuring uninterrupted treatment whilst managing costs effectively.
Clinical Evidence Supporting Wegovy vs Mounjaro Dosage Decisions
The STEP clinical trial programme provides robust evidence for Wegovy's dose-escalation approach, with the 2.4mg maintenance dose demonstrating significant efficacy in weight management. In STEP 1, participants taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The structured dose escalation to 2.4mg proved essential for optimising both tolerability and therapeutic outcomes.
Mounjaro's clinical evidence stems from the SURMOUNT trials, showing dose-dependent efficacy across its 5mg, 10mg, and 15mg maintenance doses. When considering switching between these medications, the clinical evidence suggests that both follow established dose-escalation protocols designed to maximise patient outcomes whilst minimising adverse effects, though individual responses may vary significantly.
How Wegovy Works: GLP-1 Mechanism at Therapeutic Doses
Wegovy (semaglutide) functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone GLP-1 that regulates appetite and glucose metabolism. At therapeutic doses from 0.25mg through to 2.4mg maintenance, Wegovy binds to GLP-1 receptors in the brain's appetite centres, promoting feelings of satiety and reducing food cravings. The medication slows gastric emptying, meaning food remains in the stomach longer, contributing to prolonged fullness after smaller meals. This mechanism operates dose-dependently, with the 2.4mg maintenance dose providing optimal receptor engagement for sustained weight management alongside a reduced-calorie diet and increased physical activity. The once-weekly injection schedule maintains consistent therapeutic levels throughout the week.
Wegovy vs Mounjaro Dosage: EverydayMeds Ordering Process
Switching between Wegovy and Mounjaro through EverydayMeds begins with our 3-minute online clinical assessment, designed to capture your current medication history, dosing experience, and treatment goals. Our prescribers review your assessment within 3 working days (or 24 hours with express service), determining the most appropriate starting dose based on your previous GLP-1 experience and any switching considerations. Once approved, your prescription-only medicine ships via next-day delivery using our temperature-controlled cold-chain system, ensuring medication integrity from our GPhC-registered pharmacy (#9012878) directly to your door. The seamless process eliminates prescription transfer delays, maintaining treatment continuity whilst facilitating cost-effective medication switching. Our clinical team remains available throughout your transition for dosing guidance and ongoing support.
Storage and Practical Considerations for Wegovy vs Mounjaro Dosage
Wegovy offers superior storage flexibility compared to Mounjaro, maintaining stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration, versus Mounjaro's 21-day room temperature limit. This advantage proves particularly valuable for travel or lifestyle flexibility when switching medications. Wegovy's FlexTouch pen delivers precise doses through its user-friendly interface, with clear dose escalation markings from 0.25mg through 2.4mg. The medication requires refrigerated storage at 2-8°C before first use, and the gradual dose escalation schedule allows patients to adapt to increasing therapeutic levels whilst monitoring individual tolerance. Each pen contains multiple doses, with the 2.4mg maintenance pen providing 4 weekly injections, optimising both convenience and cost-effectiveness for long-term weight management treatment.
Wegovy vs Mounjaro Dosage Switching: Transition Strategies and Timeline
The transition between Wegovy vs Mounjaro dosage regimens requires individualised planning based on your current treatment phase and therapeutic response. Patients switching from Mounjaro to Wegovy typically begin at the 0.5mg or 1mg dose rather than the 0.25mg starter dose, depending on their established GLP-1 tolerance and previous maintenance dose. The timing of the switch usually involves completing your current injection cycle before initiating the new medication, with potential overlap periods to maintain therapeutic continuity.
Conversely, patients switching from Wegovy to Mounjaro may start at the 2.5mg or 5mg dose based on their Wegovy maintenance level, with careful monitoring during the initial 4-8 weeks. The switching timeline typically spans 2-4 weeks for complete transition, during which patients monitor for any changes in appetite control, side effects, or therapeutic efficacy, ensuring optimal outcomes throughout the medication change process.
Complete Your Wegovy vs Mounjaro Dosage Switch with EverydayMeds
Ready to explore switching between these prescription-only weight management medications? EverydayMeds stocks both Wegovy and Mounjaro, enabling seamless transitions without prescription transfer complications or supply interruptions. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to access our competitive pricing structure starting from £79.99. Our clinical assessment process evaluates your switching requirements, current dose equivalency, and optimal transition pathway for maintaining therapeutic continuity. Begin your switch today through our secure online platform, backed by our GPhC-registered pharmacy (#9012878) and expert clinical oversight for confident medication management.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
